Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Exenatide cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Exenatide has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Exenatide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Exenatide cycle length?
No cycle is defined. Exenatide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Exenatide?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Exenatide dosing reference Full research page

References

  1. BYETTA (exenatide) injection, for subcutaneous use, prescribing information (DailyMed, effective 09/2025) FDA label (DailyMed). 2025
  2. Exenatide injection (Amneal), prescribing information (DailyMed, effective 05/2026) FDA label (DailyMed). 2026
  3. Drugs@FDA (openFDA) application records for exenatide (NDA 021773, NDA 022200, NDA 209210, ANDA 206697) U.S. FDA. 2026
  4. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care. 2005
  5. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL) N Engl J Med. 2017
  6. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial Lancet. 2025
  7. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom J Biol Chem. 1992
  8. World Anti-Doping Agency Prohibited List 2026 (online version) WADA. 2026
  9. PubChem compound record for exenatide PubChem. 2026